111 related articles for article (PubMed ID: 11550291)
1. Cost-effectiveness analysis with risk aversion.
Zivin JG
Health Econ; 2001 Sep; 10(6):499-508. PubMed ID: 11550291
[TBL] [Abstract][Full Text] [Related]
2. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria.
Coyle D; Buxton MJ; O'Brien BJ
Health Econ; 2003 May; 12(5):421-7. PubMed ID: 12720259
[TBL] [Abstract][Full Text] [Related]
3. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis and innovation.
Jena AB; Philipson TJ
J Health Econ; 2008 Sep; 27(5):1224-36. PubMed ID: 18619695
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points.
Bloomfield DJ; Krahn MD; Neogi T; Panzarella T; Smith TJ; Warde P; Willan AR; Ernst S; Moore MJ; Neville A; Tannock IF
J Clin Oncol; 1998 Jun; 16(6):2272-9. PubMed ID: 9626231
[TBL] [Abstract][Full Text] [Related]
6. Indirect costs and cost-effectiveness analysis.
Ernst R
Value Health; 2006; 9(4):253-61. PubMed ID: 16903995
[TBL] [Abstract][Full Text] [Related]
7. Biases in Individualized Cost-effectiveness Analysis: Influence of Choices in Modeling Short-Term, Trial-Based, Mortality Risk Reduction and Post-Trial Life Expectancy.
van Klaveren D; Wong JB; Kent DM; Steyerberg EW
Med Decis Making; 2017 Oct; 37(7):770-778. PubMed ID: 28854143
[TBL] [Abstract][Full Text] [Related]
8. Representing uncertainty: the role of cost-effectiveness acceptability curves.
Fenwick E; Claxton K; Sculpher M
Health Econ; 2001 Dec; 10(8):779-87. PubMed ID: 11747057
[TBL] [Abstract][Full Text] [Related]
9. Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
von der Schulenburg J; Vauth C; Mittendorf T; Greiner W
Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539
[TBL] [Abstract][Full Text] [Related]
10. Economic foundations of cost-effectiveness analysis.
Garber AM; Phelps CE
J Health Econ; 1997 Feb; 16(1):1-31. PubMed ID: 10167341
[TBL] [Abstract][Full Text] [Related]
11. Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach.
Elbasha EH
Health Econ; 2005 May; 14(5):457-70. PubMed ID: 15386661
[TBL] [Abstract][Full Text] [Related]
12. How Uncertainty Matters Under Risk Neutrality.
Glynn D; Lomas J
Value Health; 2023 Aug; 26(8):1151-1154. PubMed ID: 37160252
[TBL] [Abstract][Full Text] [Related]
13. Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data.
Willan AR; O'Brien BJ
Health Econ; 1999 May; 8(3):203-11. PubMed ID: 10348415
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer.
Konski A
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1373-8. PubMed ID: 15590167
[TBL] [Abstract][Full Text] [Related]
15. Aggregate Distributional Cost-Effectiveness Analysis of Health Technologies.
Love-Koh J; Cookson R; Gutacker N; Patton T; Griffin S
Value Health; 2019 May; 22(5):518-526. PubMed ID: 31104729
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness acceptability curves--caveats quantified.
Jakubczyk M; Kamiński B
Health Econ; 2010 Aug; 19(8):955-63. PubMed ID: 19688780
[TBL] [Abstract][Full Text] [Related]
17. Expected value of information and decision making in HTA.
Eckermann S; Willan AR
Health Econ; 2007 Feb; 16(2):195-209. PubMed ID: 16981193
[TBL] [Abstract][Full Text] [Related]
18. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
Bryan S; Williams I; McIver S
Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
[TBL] [Abstract][Full Text] [Related]
19. Constant and decreasing timing aversion for saving lives.
Cairns J; van der Pol M
Soc Sci Med; 1997 Dec; 45(11):1653-9. PubMed ID: 9428085
[TBL] [Abstract][Full Text] [Related]
20. Eliciting stated preferences for health-technology adoption criteria using paired comparisons and recommendation judgments.
Johnson FR; Backhouse M
Value Health; 2006; 9(5):303-11. PubMed ID: 16961548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
